Bi-weekly very-high-dose lapatinib: an easy-to-use active option in HER-2-positive breast cancer patients with meningeal carcinomatosis.
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France. pernelle.lavaud@gmail.com.
P
P
Lavaud
Department of Medical Oncology, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil University, Paris, France.
B
B
Rousseau
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
Z
Z
Ajgal
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
J
J
Arrondeau
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
O
O
Huillard
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
J
J
Alexandre
Department of Pharmacology, Henri Mondor Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris Est Créteil University, Paris, France.
A
A
Hulin
Department of Medical Oncology, Cochin Teaching Hospital, Assistance Publique Hôpitaux de Paris, Paris-Descartes University, Paris, France.
F
F
Goldwasser
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000473:pathology*; D003967:Diarrhea / Q000139:chemically induced; D005260:Female; D006801:Humans; D000077341:Lapatinib; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008279:Magnetic Resonance Imaging; D055756:Meningeal Carcinomatosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000556:secondary; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D000068878:Trastuzumab / Q000627:therapeutic use; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D000077341:Lapatinib; D011799:Quinazolines; D018719:Erb-b2 Receptor Tyrosine Kinases; D000068878:Trastuzumab; C508053:ERBB2 protein, human